On January 30, 2026, Immutep told the Securities and Exchange Commission that its TACTI-004 trial was showing “strong operational progress” and that the planned interim futility analysis remained “on track for the first quarter of 2026.” A class action now says that was not the whole story.
Rosen Law Firm has reminded buyers of Immutep American Depositary Receipts (Nasdaq: IMMP) that they have until July 6, 2026 to ask the court to make them lead plaintiff. The class period runs from March 24, 2025 through March 12, 2026, inclusive.
The claims
TACTI-004 tests eftilagimod alfa, also called efti. According to the lawsuit, the defendants made false or misleading statements, or hid the status and prospects of the trial, by pointing to positive efficacy and safety readouts from other studies. The complaint names Immutep’s earlier TACTI-002 and INSIGHT-003 trials, both of which produced positive top-line results.
The suit says the company knew, or recklessly disregarded, that the study was at increased risk of missing its primary efficacy or safety endpoints. Immutep, the plaintiffs say, had access to internal clinical data, analyses and reports on the trial and on its planned interim futility evaluation. When the facts came out, the lawsuit says, investors suffered damages. The allegations have not been proven.
For investors
A class action has already been filed. A lead plaintiff acts on behalf of other class members and directs the litigation, and anyone who wants that role must move the court by July 6.
No class has been certified. Until one is, investors are not represented by counsel unless they hire a lawyer, and they can choose their own. They can also do nothing and remain absent class members. Rosen says the ability to share in any future recovery does not depend on serving as lead plaintiff.
Rosen says Immutep ADR purchasers may be entitled to compensation under a contingency fee arrangement, with no out-of-pocket fees or costs. Phillip Kim of the firm can be reached toll-free at 866-767-3653.
